This is a working overview of DAC group, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
==== Accessory pigments in photosynthesis ==== MAAs are able to absorb UV light. A study published in 1976 demonstrated that an increase in MAA content was associated with an increase in photosynthetic respiration. Further studies done in marine cyanobacteria showed that the MAAs synthesized in response to UV-B correlated with an increase in photosynthetic pigments. Though not absolute proof, these findings do implicate MAAs as accessory pigments to photosynthesis.
On September 20, 2024, the United States Court of Appeals for the Third Circuit overturned that decision, holding that federal law did not block plaintiffs' state law claims against Merck over Fosamax. As of June 30, 2024, about 3,115 lawsuits over Fosamax were still pending against Merck in both federal and state courts in the United States.
=== Protein degradation === Arginine phosphorylation by McsB kinase marks proteins for degradation by a Clp protease. The arginine phosphorylation system, which is widely distributed across Gram-positive bacteria, appears to be functionally analogous to the eukaryotic ubiquitin–proteasome system.
Sources: en.wikipedia.org
Unit I – Bonthapally: The primary manufacturing hub situated in Bonthapally village, Medak District, Telangana, with multiple production blocks including kilo labs and quality assurance laboratories. It holds approvals from major regulatory agencies and supports commercial API production. Unit II – Pashamylaram: A large-scale manufacturing facility comprising multiple production blocks, an engineering workshop, and warehouses. Unit III – Gaddapotharam: A multi-product facility designed for advanced intermediates and APIs, with analytical development and pilot plant capabilities. R&D Centre – Bonthapally: Research and development centre with a team of approximately 360 scientists, pilot labs, and analytical capabilities to catalyze process development and technology transfer.
== Side effects == Possible and rare side effects may include dizziness, hypotension, indigestion, allergic reactions (itchy skin) after high doses, hypothermia, fatigue. And lowered blood pressure and/or body temperature decreased by 1 to 1.5 °C. Blood pressure and body temperature return to normal after completion of treatment.
=== Myanmar === Myanmar, which has experienced civil war since 2021, has restricted private vehicle use to alternate days, and there are long queues at petrol stations. The country is lacking in refineries, and it relies on oil products imported from Thailand, Vietnam, and Singapore.
== Collins English Dictionary == The Collins English Dictionary has announced a Word of the Year every year since 2013, and prior to this, announced a new 'word of the month' each month in 2012. Published in Glasgow, UK, Collins English Dictionary has been publishing English dictionaries since 1819. Toward the end of each calendar year, Collins release a shortlist of notable words or those that have come to prominence in the previous 12 months. The shortlist typically comprises ten words, though in 2014 only four words were announced as the Word of the Year shortlist. The Collins Words of the Year are selected by the Collins Dictionary team across Glasgow and London, consisting of lexicographers, editorial, marketing, and publicity staff, though previously the selection process has been open to the public. Whilst the word is not required to be new to feature, the appearance of words in the list is often supported by usage statistics and cross-reference against Collins' extensive corpus to understand how language may have changed or developed in the previous year. The Collins Word of the Year is also not restricted to UK language usage, and words are often chosen that apply internationally as well, for example, fake news in 2017.
Sources: en.wikipedia.org
== Application to drugs == The hydrogen bond is relevant to drug design. According to Lipinski's rule of five the majority of orally active drugs have no more than five hydrogen bond donors and fewer than ten hydrogen bond acceptors. These interactions exist between nitrogen–hydrogen and oxygen–hydrogen centers. Many drugs do not, however, obey these "rules".
Candesartan is administered clinically as the cyclohexyl 1-hydroxy ethyl carbonate ester, known as candesartan cilexetil. It is a cascading prodrug that is completely metabolised by esterases in the intestinal wall during absorption, releasing the active candesartan moiety. In the first step of the activation process, the carbonate group is hydrolyzed, releasing carbon dioxide. This reaction also produces cyclohexanol, a relatively non-toxic byproduct that contributes to the favorable safety profile of the prodrug. Another side product of the cascading mechanism is acetic acid, derived from the hydrolysis of the O-CH(CH3)- group; like cyclohexanol, it is also non-toxic and poses minimal risk during drug activation. The use of the prodrug form, candesartan cilexetil, enhances the bioavailability of candesartan. However, its absolute bioavailability remains relatively low, ranging from approximately 15% when administered as tablets to 40% as an oral solution. Candesartan has an IC50 of 15 μg/kg. The active form of candesartan is not used directly in clinical practice, as it would require higher dosing and is associated with a less favorable adverse event profile.
=== New lethal injection protocols === The Ohio protocol, developed after the incomplete execution of Romell Broom, aims to ensure the rapid and painless onset of anesthesia by only using sodium thiopental and eliminating the use of Pavulon and potassium as the second and third drugs, respectively. It also provides for a secondary fail-safe measure using intramuscular injection of midazolam, followed by sufentanil or hydromorphone, in the event intravenous administration of the sodium thiopental proves problematic. The first state to switch to use midazolam as the first drug in a new three-drug protocol was Florida on October 15, 2013. Then on November 14, 2013, Ohio made the same move.
Although the plebiscite showed a clear view for unofficial majority, Robinson still insisted to have sanitary affairs placed directly under Government control. The then Secretary of State Joseph Chamberlain was not pleased with the Governor's decision of a plebiscite and stated that "it is inconsistent with Crown Colony government to seek the guidance of a plebiscite; and in no community whatever whether Crown Colony or not, can a satisfactory solution of a question, in which the whole body of the ratepayers and many outside that body are interested, be induced from an expression of the opinions of one section alone." Moreover, in this case the plebiscite had led to a result which was opposed to the Governor's own advice. Chamberlain refused any constitutional changes to the Sanitary Board. The election for the unofficial members resumed in 1899. The Sanitary Department was not established until the Public Health and Buildings Ordinance was passed in 1903. Hong Kong had to wait until 1936 and the creation of the Urban Council for any further advance toward a municipal council. Nevertheless, the other two suggestions by Lord Ripon were soon carried out, an unofficial member and an official member appointed to the Legislative Council respectively and two unofficial members who were the senior members the Legislative Council appointed to the Executive Council. Wei Yuk was the newly appointed unofficial member to the Legislative Council as one of the two Chinese representative alongside Ho Kai who had been the member since 1890.
== Effects on weather patterns == El Niño affects the global climate and disrupts normal weather patterns, which can lead to intense storms in some places and droughts in others. In June 2026, the UN warned that El Niño could become one of the strongest in decades, bringing extreme weather such as droughts, floods, storms and raising the chances of wildfires.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.